In vivo treatment of human acute promyelocytic leukemia with a histone deacetylase inhibitor, FR901228.

被引：0
|
作者：
Kosugi, H
Towatari, M
Ito, M
Ito, M
Saito, H
Naoe, T
机构：
[1] Nagoya Univ, Sch Med, Dept Internal Med 1, Nagoya, Aichi 466, Japan
[2] Cent Inst Expt Anim, Kawasaki, Kanagawa, Japan
[3] Nagoya Univ, Sch Med, Dept Infect Dis, Nagoya, Aichi 466, Japan
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2261
引用
收藏
页码：505A / 505A
页数：1
相关论文
共 50 条
  • [21] Application of Histone Deacetylase Inhibitor in Acute Myeloid Leukemia
    Chen, Dan-Dan
    Qin, Ke-Ning
    Lu, Chun-Li
    Zeng, Jian-Ye
    Wang, Xiao-Min
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2024, 51 (06) : 1393 - 1405
  • [22] Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms
    Sandor, V
    Bakke, S
    Robey, RW
    Kang, MH
    Blagosklonny, MV
    Bender, J
    Brooks, R
    Piekarz, RL
    Tucker, E
    Figg, WD
    Chan, KK
    Goldspiel, B
    Fojo, AT
    Balcerzak, SP
    Bates, SE
    CLINICAL CANCER RESEARCH, 2002, 8 (03) : 718 - 728
  • [23] FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells
    Sato, N
    Ohta, T
    Kitagawa, H
    Kayahara, M
    Ninomiya, I
    Fushida, S
    Fujimura, T
    Nishimura, G
    Shimizu, K
    Miwa, K
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2004, 24 (03) : 679 - 685
  • [24] The histone deacetylase inhibitor FR901228 (depsipeptide) restores expression and function of pseudo-null p53
    Kitazono, M
    Bates, S
    Fok, P
    Fojo, T
    Blagosklonny, MV
    CANCER BIOLOGY & THERAPY, 2002, 1 (06) : 665 - 668
  • [25] The histone deacetylase inhibitor depsipeptide (FR901228) enhances the cytotoxic activity of Ad5-TRAIL against human prostate tumor cells
    Griffith, TS
    Moore, J
    Van Oosten, R
    MOLECULAR THERAPY, 2004, 9 : S361 - S362
  • [26] Adenovirus transgene expression is enhanced in normal and malignant hematopoietic cells by pretreatment with the histone deacetylase inhibitor FR901228 (depsipeptide).
    Rao, VK
    Kitazono, M
    Robey, R
    Aikou, T
    Bates, SE
    Fojo, T
    Goldsmith, ME
    BLOOD, 2001, 98 (11) : 424A - 424A
  • [27] Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines
    Kano, Yasuhiko
    Akutsu, Miyuki
    Tsunoda, Saburo
    Izumi, Tohru
    Kobayashi, Hiroyuki
    Mano, Hiroyuki
    Furukawa, Yusuke
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (01) : 31 - 40
  • [28] Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines
    Yasuhiko Kano
    Miyuki Akutsu
    Saburo Tsunoda
    Tohru Izumi
    Hiroyuki Kobayashi
    Hiroyuki Mano
    Yusuke Furukawa
    Investigational New Drugs, 2007, 25 : 31 - 40
  • [29] Analysis of the effect of the novel histone deacetylase inhibitor, depsipeptide (FK228/FR901228) on mantle cell lymphoma.
    Paner, GP
    Alkan, S
    BLOOD, 2004, 104 (11) : 685A - 685A
  • [30] Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood
    Xiao, JJ
    Byrd, J
    Marcucci, G
    Grever, M
    Chan, KK
    RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2003, 17 (08) : 757 - 766
12345